VIENNA, Va.–(BUSINESS WIRE)–

CEL-SCI Corporation (NYSE MKT:CVM) today announced its Phase III Head and Neck Cancer clinical trial of its investigational cancer immunotherapy treatment Multikine* (Leukocyte Interleukin, Injection) has activated its first U.S. clinical trial expansion site at 21st Century Oncology in Greenville, North Carolina. The trial is already active in dozens of hospitals and clinical centers in 12 countries.

21st Century Oncology is the largest global, physician-led provider of integrated cancer care services, operating 166 treatment centers, with 133 centers in 16 U.S. states and 33 centers in six Latin American countries. The Greenville, North Carolina facility is led by Dr. Ron Allison, a board-certified radiation oncologist specializing in Head and Neck Cancer. Dr. Allison, who is serving as the Principal Investigator of CEL-SCI’s Phase III study at the site, has authored several books in the field of oncology and holds several patents addressing radiation isometer measurement devices/visualization and ultrasound distance measurement devices.

“Our goal is to have between 10 and 15 U.S. clinical centers participating in our Phase III trial. We should be there by this summer.” stated CEL-SCI Chief Executive Officer Geert Kersten.

About Multikine

Multikine (Leukocyte Interleukin, Injection) is an immunotherapeutic agent that is being tested in a randomized, controlled, global pivotal Phase III clinical trial as a potential first-line treatment for advanced primary head and neck cancer. If approved for use following completion of CEL-SCI’s clinical development program for head and neck cancer, Multikine would be a different type of therapy in the fight against cancer; one that appears to have the potential to work with the body’s natural immune system in the fight against tumors. CEL-SCI is aiming to complete enrollment of subjects to the Phase III head and neck cancer study by the end of 2015. The trial is expected to expand into a total of approximately 100-110 clinical centers in about 20 countries.

In October 2013, CEL-SCI announced that it had signed a CRADA (Cooperative Research and Development Agreement) with the US Naval Medical Center, San Diego, to develop Multikine as a potential treatment for HIV/HPV co-infected men and women with peri-anal warts. CEL-SCI also announced that it entered into two new co-development agreements with Ergomed to further clinically develop Multikine for cervical dysplasia/neoplasia in women who are co-infected with HIV and HPV and for peri-anal warts in men and women who are co-infected with HIV and HPV.

WILMINGTON, Mass., March 5, 2014 /PRNewswire/ — Implant Sciences Corporation (OTCQB:IMSC), a high technology supplier of systems and sensors for homeland security and defense markets, today announced that officials from the United States Transportation Security Administration (TSA) and the Canadian Air Transport Security Authority (CATSA) toured Implant Sciences’ headquarters and 58,000 sq. ft. manufacturing facility in Wilmington, Massachusetts on Tuesday, January 28, 2014.

TSA and CATSA work together in a partnership to explore existing and new technologies. During the tour, officials met with Implant Sciences’ executives and staff and learned about the manufacturing processes of the QS-B220 and QS-H150 explosives trace detectors (ETD), which are currently used around the world in mission critical security applications. The Company also provided updates on new ETD technologies being developed for future applications.

Implant Sciences President and CEO, Glenn Bolduc, commented, “We were pleased to have the opportunity to host officials from the TSA and CATSA. These agencies play a critical role in keeping passengers and aviation facilities safe. This visit was an opportunity to demonstrate to some of the biggest security equipment procurers in the world that Implant Sciences is a small business that can deliver quality security technology. We trust that they were impressed by our state-of-the-art manufacturing facility and by the caliber of our personnel.”

The Company’s QS-B220 desktop ETD has received TSA qualification for air cargo screening and is currently is in the final stages of TSA qualification for checkpoint and checked baggage screening.

About Implant Sciences

Implant Sciences is the leader in next generation Explosives Trace Detection (ETD) technology. In January 2013, the Company became only the third ETD manufacturer, and the sole American-owned company, to currently have product approval from the US Transportation Security Administration. Implant Sciences has developed proprietary technologies used in its commercial explosives and drugs trace detection systems, which ship to a growing number of locations domestically and internationally. Implant Sciences’ QS-H150 portable explosives trace detector has received Qualified Anti-Terrorism Technology Designation and, in addition to receiving TSA qualification for air cargo screening, the Company’s QS-B220 has also received STAC certification, a Developmental Testing & Evaluation (DT&E) Designation by the U.S. Department of Homeland Security under the Support Anti-terrorism by Fostering Effective Technology Act of 2002 (the SAFETY Act), and the GSN 2013 Homeland Security Award for “Best Explosives Detection Solution”. For further details on the Company and its products, please visit the Company’s website at http://www.implantsciences.com.